Cross-institution positioning
Aug 14, 2026Strong institutional accumulation. 2 accumulating, 1 reducing across 3 comparable institutions.
Source: Schedule 13 researchTango Therapeutics, Inc.
Latest stored close $21.83 as of Oct 7, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Strong institutional accumulation. 2 accumulating, 1 reducing across 3 comparable institutions.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 0 purchases by 0 reporting owners and 8 sales by 2 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/54 non-amendment material events in the last 90 days; 1 capital-related filing/event; Latest classified evidence: Other event. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue -100.0% YoY; Net income -42.4% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 62% through its reported 52-week range; +250.3% over one year.
Source: Stored historical price seriesFiled Aug 14, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Crystal Adam | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 27.0K | $0.00 | Direct | Oct 5, 2026 |
| Oct 1, 2026 | Crystal Adam | SOpen-market or private sale | Common Stock | 600 | $25.32 | Direct | Oct 5, 2026 |
| Oct 1, 2026 | Crystal Adam | SOpen-market or private sale | Common Stock | 26.4K | $24.45 | Direct | Oct 5, 2026 |
| Oct 1, 2026 | Crystal Adam | MExercise or conversion of derivative | Common Stock | 27.0K | $5.20 | Direct | Oct 5, 2026 |
| Sep 22, 2026 | Newcomb Jessica | SOpen-market or private sale | Common Stock | 2.4K | $25.17 | Direct | Sep 24, 2026 |
| Sep 22, 2026 | Newcomb Jessica | SOpen-market or private sale | Common Stock | 5.1K | $23.97 | Direct | Sep 24, 2026 |
| Sep 22, 2026 | Newcomb Jessica | SOpen-market or private sale | Common Stock | 700 | $22.80 | Direct | Sep 24, 2026 |
| Sep 1, 2026 | Crystal Adam | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 27.0K | $0.00 | Direct | Sep 3, 2026 |
| Sep 1, 2026 | Crystal Adam | SOpen-market or private sale | Common Stock | 27.0K | $22.37 | Direct | Sep 3, 2026 |
| Sep 1, 2026 | Crystal Adam | MExercise or conversion of derivative | Common Stock | 27.0K | $5.20 | Direct | Sep 3, 2026 |
| Aug 3, 2026 | Crystal Adam | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 27.0K | $0.00 | Direct | Aug 5, 2026 |
| Aug 3, 2026 | Crystal Adam | SOpen-market or private sale | Common Stock | 21.7K | $27.35 | Direct | Aug 5, 2026 |
| Aug 3, 2026 | Crystal Adam | SOpen-market or private sale | Common Stock | 5.3K | $26.79 | Direct | Aug 5, 2026 |
| Aug 3, 2026 | Crystal Adam | MExercise or conversion of derivative | Common Stock | 27.0K | $5.20 | Direct | Aug 5, 2026 |
| Jul 1, 2026 | Crystal Adam | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 27.0K | $0.00 | Direct | Jul 2, 2026 |
| Jul 1, 2026 | Crystal Adam | SOpen-market or private sale | Common Stock | 7.4K | $30.25 | Direct | Jul 2, 2026 |
| Jul 1, 2026 | Crystal Adam | SOpen-market or private sale | Common Stock | 19.6K | $29.34 | Direct | Jul 2, 2026 |
| Jul 1, 2026 | Crystal Adam | MExercise or conversion of derivative | Common Stock | 27.0K | $5.20 | Direct | Jul 2, 2026 |
| Jun 19, 2026 | Azelby Robert | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 35.9K | $0.00 | Direct | Jun 23, 2026 |
| Jun 19, 2026 | Azelby Robert | AGrant, award, or other acquisition | Common Stock | 5.7K | $0.00 | Direct | Jun 23, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Aug 11, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Aug 11, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Aug 11, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Aug 7, 2026 | 8-K/AAmendment | 5.02, 7.01, 9.01 | Director or executive change; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Aug 6, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Jun 23, 2026 | 8-K | 5.02, 9.01 | Director or executive change; Financial statements / exhibits | — | Filing |
| Jun 10, 2026 | 8-K | 1.01, 9.01 | Material definitive agreement; Financial statements / exhibits | — | Filing |
| Jun 10, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Jun 8, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Jun 8, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Jun 4, 2026 | 8-K | 5.07 | Shareholder vote results | — | Filing |
| May 13, 2026 | 8-K | 2.02, 5.02, 9.01 | Results of operations / financial condition; Director or executive change; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $0 | -100.0% |
| Ended Mar 31, 2026 | $0 | -100.0% |
| Ended Sep 30, 2025 | $53.8M | +363.6% |
| Ended Jun 30, 2025 | $3.2M | -84.0% |
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $62.4M | +48.3% |
| Ended Dec 31, 2024 | $42.1M | +15.2% |
| Ended Dec 31, 2023 | $36.5M | +46.9% |
| Ended Dec 31, 2022 | $24.9M | -32.9% |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Goldman Sachs Group CIK0000886982 | Jun 30, 2026 observed Aug 14, 2026 filed · 45d Initial Schedule 13G | Initial Schedule 13G | 9.7K | 6.00% | $31.26 | $25.60 | $21.83 |
| Fidelity / FMR CIK0000315066 | Mar 31, 2026 observed May 6, 2026 filed · 36d Initial Schedule 13G | Initial Schedule 13G | 9.9M +9.9M | 12.00% +12.00 pts | $20.92 | $23.62 | $21.83 |
| Vanguard Group CIK0000102909 | Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment | Reported reduction | 11 -6.8M | 12.00% +6.99 pts | $17.30 | $19.26 | $21.83 |
Compare TNGX with other securities showing similar institutional activity or recent accumulation across several tracked institutions.